BRPI0412931A - tratamento da supressão de dependência - Google Patents
tratamento da supressão de dependênciaInfo
- Publication number
- BRPI0412931A BRPI0412931A BRPI0412931-8A BRPI0412931A BRPI0412931A BR PI0412931 A BRPI0412931 A BR PI0412931A BR PI0412931 A BRPI0412931 A BR PI0412931A BR PI0412931 A BRPI0412931 A BR PI0412931A
- Authority
- BR
- Brazil
- Prior art keywords
- buprenorphine
- dosage form
- dosage
- days
- dosing period
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 7
- 229960001736 buprenorphine Drugs 0.000 abstract 7
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000006211 transdermal dosage form Substances 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Materials Engineering (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Drying Of Semiconductors (AREA)
- Cephalosporin Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Abstract
"TRATAMENTO DA SUPRESSãO DE DEPENDêNCIA". A presente invenção refere-se a esquemas de buprenorfina para tratar supressão de droga ou síndrome de abstinência em uma paciente dependente de drogas ou tolerante a opiáceos, que está grávida. O método inclui tratar a supressão ou sindrome de abstinência da paciente pela administração transdérmica de uma quantidade de buprenorfina eficaz para reduzir os sintomas de supressão. Por exemplo, uma primeira forma de dosagem transdérmica que contém buprenorfina pode ser administrada por um primeiro período de dosagem que não é mais longo do que cerca de 5 dias; uma segunda forma de dosagem transdérmica que contém buprenorfina pode ser administrada por um segundo período de dosagem que não é mais longo do que cerca de 5 dias, onde a dita segunda forma de dosagem compreende a mesma dosagem de buprenorfina, ou uma dosagem de buprenorfina maior do que a dita primeira dosagem; e uma terceira forma de dosagem transdérmica que contém buprenorfina pode ser administrada por um terceiro período de dosagem de pelo menos 2 dias, onde a terceira forma de dosagem compreende a mesma dosagem ou uma dosagem maior de buprenorfina do que a segunda forma de dosagem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49040703P | 2003-07-25 | 2003-07-25 | |
| PCT/US2004/024010 WO2005011579A2 (en) | 2003-07-25 | 2004-07-26 | Treatment of dependence withdrawal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412931A true BRPI0412931A (pt) | 2006-09-26 |
Family
ID=34115390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412931-8A BRPI0412931A (pt) | 2003-07-25 | 2004-07-26 | tratamento da supressão de dependência |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8637073B2 (pt) |
| EP (1) | EP1646328B1 (pt) |
| JP (2) | JP2007500134A (pt) |
| KR (1) | KR100829492B1 (pt) |
| CN (1) | CN1829482B (pt) |
| AT (1) | ATE375149T1 (pt) |
| AU (1) | AU2004261182B2 (pt) |
| BR (1) | BRPI0412931A (pt) |
| CA (1) | CA2530005C (pt) |
| CY (1) | CY1107262T1 (pt) |
| DE (1) | DE602004009449T2 (pt) |
| DK (1) | DK1646328T3 (pt) |
| EA (1) | EA009921B1 (pt) |
| ES (1) | ES2295929T3 (pt) |
| GE (1) | GEP20125454B (pt) |
| HR (1) | HRP20070476T3 (pt) |
| IL (1) | IL173346A (pt) |
| IS (1) | IS2630B (pt) |
| MA (1) | MA28004A1 (pt) |
| MX (1) | MXPA06000991A (pt) |
| NO (1) | NO333189B1 (pt) |
| NZ (1) | NZ545505A (pt) |
| PL (1) | PL1646328T3 (pt) |
| PT (1) | PT1646328E (pt) |
| SI (1) | SI1646328T1 (pt) |
| UA (1) | UA81056C2 (pt) |
| WO (1) | WO2005011579A2 (pt) |
| ZA (1) | ZA200510069B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| EP1913938A1 (en) * | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| WO2004054553A1 (en) | 2002-12-13 | 2004-07-01 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| CA2530005C (en) | 2003-07-25 | 2011-09-27 | Bruce E. Reidenberg | Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman |
| CN101321554A (zh) * | 2005-09-30 | 2008-12-10 | Tti优而美株式会社 | 使用类阿片激动剂和/或类阿片拮抗剂的经皮药物输送系统、装置和方法 |
| WO2009106831A2 (en) * | 2008-02-28 | 2009-09-03 | Syntropharma Limited | Pharmaceutical composition |
| US8163731B2 (en) * | 2008-08-20 | 2012-04-24 | Rhodes Technologies | Method and dosage regimens for eliminating a chemical substance in blood |
| WO2011116243A1 (en) | 2010-03-17 | 2011-09-22 | Method Products, Inc. | Liquid cleaning compositions with lower freezing point |
| US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
| TW201307553A (zh) | 2011-07-26 | 2013-02-16 | Dow Agrosciences Llc | 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術 |
| TWI522101B (zh) * | 2012-04-17 | 2016-02-21 | 普渡製藥有限合夥事業 | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| WO2017120417A1 (en) | 2016-01-08 | 2017-07-13 | Ohio State Innovation Foundation | Treatments and prevention of opioid neonatal abstinence syndrome |
| CA3068036A1 (en) | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | Use to buprenorphine in combination with an opioid to treat pain |
| CN107648234A (zh) * | 2017-08-04 | 2018-02-02 | 中国人民解放军第二军医大学 | 一种治疗吗啡成瘾戒断症状的阿片类药物组合物 |
| CA3066284A1 (en) * | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
| WO2021043771A1 (en) * | 2019-09-02 | 2021-03-11 | Camurus Ab | Formulations and treatment methods |
| JP2024506861A (ja) | 2021-02-01 | 2024-02-15 | クリア サイエンティフィック，インク． | 物質使用障害の治療のための隔離化合物及びその使用 |
| WO2024036337A2 (en) * | 2022-08-12 | 2024-02-15 | Bio Ventures, Llc | Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4058599A (en) * | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
| DE3939376C1 (pt) | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| EP0432945A1 (en) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | A transdermal delivery system for treatment of cocaine and heroin addiction |
| US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
| JPH06183956A (ja) * | 1992-12-24 | 1994-07-05 | Teisan Seiyaku Kk | 安定な貼付用の製剤 |
| JP2819236B2 (ja) * | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
| WO2003037313A2 (en) * | 2001-10-31 | 2003-05-08 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
| DK1485051T3 (da) | 2002-03-20 | 2008-09-08 | Euro Celtique Sa | Fremgangsmåde til indgivelse af buprenorphin til behandling af depression |
| WO2004054553A1 (en) * | 2002-12-13 | 2004-07-01 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
| WO2004103317A2 (en) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
| CA2530005C (en) | 2003-07-25 | 2011-09-27 | Bruce E. Reidenberg | Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman |
-
2004
- 2004-07-26 CA CA2530005A patent/CA2530005C/en not_active Expired - Fee Related
- 2004-07-26 JP JP2006521307A patent/JP2007500134A/ja active Pending
- 2004-07-26 MX MXPA06000991A patent/MXPA06000991A/es active IP Right Grant
- 2004-07-26 UA UAA200602136A patent/UA81056C2/uk unknown
- 2004-07-26 GE GEAP20049184A patent/GEP20125454B/en unknown
- 2004-07-26 BR BRPI0412931-8A patent/BRPI0412931A/pt not_active Application Discontinuation
- 2004-07-26 AT AT04779186T patent/ATE375149T1/de active
- 2004-07-26 HR HR20070476T patent/HRP20070476T3/xx unknown
- 2004-07-26 SI SI200430545T patent/SI1646328T1/sl unknown
- 2004-07-26 KR KR1020067001688A patent/KR100829492B1/ko not_active Expired - Fee Related
- 2004-07-26 CN CN2004800215633A patent/CN1829482B/zh not_active Expired - Fee Related
- 2004-07-26 NZ NZ545505A patent/NZ545505A/en not_active IP Right Cessation
- 2004-07-26 EA EA200600200A patent/EA009921B1/ru not_active IP Right Cessation
- 2004-07-26 DE DE602004009449T patent/DE602004009449T2/de not_active Expired - Lifetime
- 2004-07-26 AU AU2004261182A patent/AU2004261182B2/en not_active Ceased
- 2004-07-26 PL PL04779186T patent/PL1646328T3/pl unknown
- 2004-07-26 DK DK04779186T patent/DK1646328T3/da active
- 2004-07-26 EP EP04779186A patent/EP1646328B1/en not_active Expired - Lifetime
- 2004-07-26 PT PT04779186T patent/PT1646328E/pt unknown
- 2004-07-26 WO PCT/US2004/024010 patent/WO2005011579A2/en not_active Ceased
- 2004-07-26 US US10/566,121 patent/US8637073B2/en active Active
- 2004-07-26 ES ES04779186T patent/ES2295929T3/es not_active Expired - Lifetime
-
2005
- 2005-12-12 ZA ZA200510069A patent/ZA200510069B/en unknown
- 2005-12-19 IS IS8187A patent/IS2630B/is unknown
-
2006
- 2006-01-24 IL IL173346A patent/IL173346A/en not_active IP Right Cessation
- 2006-02-23 MA MA28830A patent/MA28004A1/fr unknown
- 2006-02-24 NO NO20060913A patent/NO333189B1/no not_active IP Right Cessation
-
2008
- 2008-01-08 CY CY20081100020T patent/CY1107262T1/el unknown
-
2011
- 2011-08-18 JP JP2011179129A patent/JP2011252020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| AU2003268144A1 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
| DE60320530D1 (de) | Missbrauchssichere transdermale opioid-verabreichungsvorrichtungen | |
| DE69823520D1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
| AU4743601A (en) | Neutral antagonists and use thereof in treating drug abuse | |
| NO20014842D0 (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| DK1572167T3 (da) | Transdermal buprenophindoseringsbehandlingsplan for analgesi | |
| IL318374A (en) | Methods of administering nalbuphine | |
| AU2009210373A1 (en) | Method and dosage regimens for eliminating a chemical substance in blood | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| BR0209613A (pt) | Composição para tratamento de dor em um mamìfero, e, método para redução ou eliminação de probabilidade de viciamento de um analgésico em um hospedeiro | |
| Naber et al. | Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients | |
| WO2008060381A3 (en) | Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| Neki et al. | Cilnidipine induced ankle edema: a rare adverse event | |
| EP1311286A4 (en) | TREATMENT OF HEPATITIS C WITH THYMOSIN AND PEG-INTERFERON |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: EURO-CELTIQUE S.A. (LU) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 9/70 (2006.01), A61K 31/485 (2006.01), A61L 1 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |